Assignee
NMD PHARMA AS
DK·8 granted patents·4 pending applications·10 citations·filing 2016–2025
Top patents by PatentIndex Score
12 records- 0179US11591284B2Compounds for the treatment of neuromuscular disordersNMD PHARMA AS·Filed 2017·Granted Feb 28, 2023·2 cites·20 claims
- 0278US11730714B2Compounds for the treatment of neuromuscular disordersNMD PHARMA AS·Filed 2018·Granted Aug 22, 2023·2 cites·20 claims
- 0377US10934244B2Compounds for use in treating neuromuscular disordersNMD PHARMA AS·Filed 2016·Granted Mar 2, 2021·4 cites·28 claims
- 0471US2026007639A1Compounds for the treatment of neuromuscular disordersNMD PHARMA AS·Filed 2025·Application pending·0 cites
- 0570US11147788B2Compounds for the treatment of neuromuscular disordersNMD PHARMA AS·Filed 2017·Granted Oct 19, 2021·2 cites·16 claims
- 0664US2026007625A1Compounds for the Treatment of Neuromuscular DisordersNMD PHARMA AS·Filed 2023·Application pending·0 cites
- 0760US12440477B2Compounds for the treatment of neuromuscular disordersNMD PHARMA AS·Filed 2018·Granted Oct 14, 2025·0 cites·24 claims
- 0847US12221425B2Process for the preparation of CIC-1 chloride channel inhibitorsNMD PHARMA AS·Filed 2020·Granted Feb 11, 2025·0 cites·22 claims
- 0946US12415771B2Compounds for the treatment of neuromuscular disordersNMD PHARMA AS·Filed 2020·Granted Sep 16, 2025·0 cites·19 claims
- 1045US2022274938A15-[(1s)-1-(4-bromophenoxy)ethyl]-2h-tetrazole derivatives and related compounds as clc-1 ion channel inhibitors for treating neuromuscular disordersNMD PHARMA AS·Filed 2020·Application pending·0 cites
- 1141US12168643B2Compounds for the treatment of neuromuscular disordersNMD PHARMA AS·Filed 2020·Granted Dec 17, 2024·0 cites·20 claims
- 1238US2019183812A1Compounds For The Treatment Of Neuromuscular DisordersNMD PHARMA AS·Filed 2018·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →